Loading the records…
Loading the records…
HR2319 is a purely procedural authorization bill requiring HHS to conduct an interagency review and produce recommendations on lung cancer research and preventive services for women. It appropriates no funding, creates no programs, and contains no mandate that directly drives revenue for any public company. No actionable market signal exists.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No market implications. This bill moves no money, creates no contracts, and imposes no compliance costs. Any perceived 'healthcare sector' impact would be purely speculative. Investors should not allocate capital based on this legislation.
On April 22, 2026, the Senate received HR2319 from the House, where it passed under suspension of the rules on April 21. The bill has been placed on the Senate Legislative Calendar. The bill's substance is limited: it directs the HHS Secretary (in consultation with Defense and VA Secretaries) to conduct an interagency review of lung cancer research gaps in women and underserved populations, and to produce recommendations on screening strategy and public education. The bill authorizes zero dollars — no funding is appropriated, no grants are created, and no procurement mandates exist. The text does not name any entity outside the federal government. The timeline for Senate floor action is uncertain; a companion bill (S1157) is also on the Senate calendar. Until either passes and the HHS review is completed and acted upon, no private-sector revenue impact can occur. No tickers merit inclusion because there is no causal chain — no mechanism in this bill obligates any private party to change behavior, incur costs, or receive revenue. Speculative association with lung cancer diagnostic or pharma companies (e.g., $LLY, $BMY, $VRTX) would be fabricated; the bill does not order, fund, or incentivize any private-sector activity. This is a data-gathering exercise with zero market consequences at this stage.
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →